USP39 and Miyoshi myopathy: Despite the absence of a pharmacological inhibitor targeting USP39, our findings indicate that inhibiting USP39 holds promise as a clinically relevant therapeutic strategy, especially for MM patients who exhibit resistance to BTZ therapy.